Individuals with depressive symptoms are at high risk of a first hospitalization for heart failure (HF) with preserved ejection fraction but not for HF with reduced ejection fraction, according to a study.
Treatment with cariprazine for patients with bipolar I depression is effective, well tolerated and relatively safe in adults with bipolar I depression in improving depressive symptoms, according to the results of a phase III study.
Specific metabolic parameters such as waist circumference and C-reactive protein are elevated, whereas high-density lipoprotein (HDL) cholesterol levels are reduced in the presence of high levels of depression and perceived stress, a study has reported.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
A text message-based cardiac support intervention that is focused on lifestyle change helps lower the occurrence of mild-to-moderate depression symptoms over 6 months in individuals with coronary heart disease (CHD), according to a secondary analysis of the TEXT ME* trial.